Member Directory - Pharmaceutical Advisory Board

Chair: Charles Flexner


  • Engage industry in conversations and serve as a key resource to identify barriers in development and to encourage production of LA/ER ARV’s
  • Identify additional experts who can make meaningful contributions to LA/ER topic-specific focus groups, including the generation of educational materials and consensus publications.

Charles W. Flexner, MD, is the Principal Investigator of the Long Acting/Extended Release Antiretroviral Resource Program (LEAP).

Conflict of Interest: Dr. Flexner has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Algernon Pharmaceuticals; Gilead; Merck; Mylan Pharmaceuticals; ViiV Healthcare. 

Daniel E Cohen, MD, is a Group Medical Director in Clinical Development at AbbVie.

Conflict of Interest: Dr. Cohen is an employee and stockholder of AbbVie.

Daria Hazuda, PhD, trained as a biochemist at the State University of New York at Stony Brook, N.Y.

Conflict of Interest: None disclosed.

Dr. James F. Rooney joined Gilead Sciences in 1996 as Vice President of Clinical Research and in 2004 became Vice President of Medical Affairs.

Conflict of Interest: None disclosed.

Bill Spreen, Pharm.D, is a Director of Research and Development at ViiV Healthcare and based in Research Triangle Park, North Carolina.

Conflict of Interest: None disclosed.